Recombinant Factor VIII (Kovaltry, BAY81-8973)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Haemophilia A

Clinical Trial

Last updated: 12/16/2025

Regulatory Approvals

EMA2/18/2016

Kovaltry

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.

Developer

BAYRY

BAYER

Related Pipeline

Colorectal Neoplasms

Pneumonia, Bacterial

Overactive Bladder

Chronic Kidney Disease

Oral Contraceptive